Status:
COMPLETED
Long-term Follow-up of Phase 1 Clinical Trial of CS10BR05(CS10BR05-MSA101)
Lead Sponsor:
Corestemchemon, Inc.
Conditions:
Multiple System Atrophy
Eligibility:
All Genders
Brief Summary
The study purpose is conducting follow-up surveillance for the incidence of adverse events and efficacy of subjects participated in phase 1 trial to evaluate the safety and tolerability of autologous ...
Detailed Description
Multiple system atrophy is a neurodegenerative disease of the central nervous system which is accompanied by signs of autonomic imbalance (orthostatic hypotension, urinary problems and erectile dysfun...
Eligibility Criteria
Inclusion
- Subjects who participated in the phase 1 clinical trial(Protocol No.: CS10BR05- MSA101) at 3 months after administering investigational product
- Subjects who give a written, signed and dated informed consent spontaneously
Exclusion
- Subjects who decided as inappropriate cases to participate in the observational study by investigator
Key Trial Info
Start Date :
August 28 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 25 2024
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT04495582
Start Date
August 28 2018
End Date
September 25 2024
Last Update
January 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yonsei University College of Medicine
Seoul, South Korea